{
  "id": 17395440,
  "title": "Beam Therapeutics surges 64% after InvestingPro’s undervalued call",
  "url": "https://urgent.news/2026/10/31/beam-therapeutics-surges-64-after-investingpros-undervalued-call",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-31T11:09:26.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/investment-ideas/beam-therapeutics-surges-64-after-investingpros-undervalued-call-93CH-4989242"
  },
  "original_language": "en",
  "account": "Beam Therapeutics Inc. (NASDAQ:BEAM) experienced a remarkable 64.51% increase in stock price following a recommendation from InvestingPro's Fair Value models, which deemed the company significantly undervalued in April 2025. The gene editing biotech's share price climbed to $29.02 by September 2026, validating the analysis. InvestingPro's Fair Value analysis combines various valuation methods to pinpoint stocks trading below their intrinsic value, providing better entry and exit points for investors. Despite a $63.6 million revenue and -$4.61 EPS, the company's Fair Value estimate was $26.37—almost 50% higher than the market price. The innovative platform enables precise DNA modifications without cutting the double helix, advancing multiple clinical programs targeting various genetic diseases. The stock faced significant volatility, including a 25.85% decline in March 2025, presenting an attractive entry point for value-focused investors. InvestingPro's models identified a 49.49% upside potential, and the stock delivered according to expectations. The investment thesis has been validated by impressive fundamental improvements, such as a 145% revenue surge to $156 million and EPS improvement to -$0.84 from -$4.61. Clinical catalysts, such as FDA's Regenerative Medicine Advanced Therapy designation and positive trial data, materialized as predicted. Notable investors like Cathie Wood's ARK funds accumulated shares, and Wells Fargo named BEAM among its top SMID-cap biotech picks for 2026. InvestingPro's Fair Value methodology aggregates multiple valuation approaches to estimate a stock's intrinsic worth, demonstrating the power of this analytical tool in identifying compelling opportunities before the broader market.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}